NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia

YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia (OSSN)

Visara is a majority-owned ophthalmology subsidiary of NovaBridge Biosciences

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Visara, Inc. ("Visara"), a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, Inc. ("NovaBridge") (NASDAQ:NBP), today announced that it has entered into an asset purchase option agreement (the "Option Agreement") with YOLO Immune ("YOLO"). The Option Agreement provides Visara with an exclusive option to acquire worldwide rights to the YOL104 Program and develop and commercialize YOL104-2 for ocular surface squamous neoplasia (OSSN). YOL104-2 is a trivalent interferon alpha (IFN-α) peptibody currently under investigation for the treatment of OSSN.

Under the terms of the Option Agreement, Visara will make an upfront payment in exchange for an exclusive option to acquire worldwide title and ownership of the YOL104 Program. If Visara exercises the option and completes the acquisition, YOLO would receive an exercise payment and would be eligible for development, regulatory and commercial milestone payments, as well as tiered royalties on net sales. Additional financial terms were not disclosed.